Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Gross Margin (2023 - 2025)

Bioregenx has reported Gross Margin over the past 3 years, most recently at 82.66% for Q4 2025.

  • For Q4 2025, Gross Margin rose 1258.0% year-over-year to 82.66%; the TTM value through Dec 2025 reached 81.08%, up 1021.0%, while the annual FY2025 figure was 81.08%, 1021.0% up from the prior year.
  • Gross Margin for Q4 2025 was 82.66% at Bioregenx, down from 83.98% in the prior quarter.
  • Over five years, Gross Margin peaked at 83.98% in Q3 2025 and troughed at 55.76% in Q4 2023.
  • A 3-year average of 72.98% and a median of 71.46% in 2023 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: crashed -376bps in 2024 and later skyrocketed 1502bps in 2025.
  • Year by year, Gross Margin stood at 55.76% in 2023, then increased by 26bps to 70.09% in 2024, then increased by 18bps to 82.66% in 2025.
  • Business Quant data shows Gross Margin for BRGX at 82.66% in Q4 2025, 83.98% in Q3 2025, and 79.03% in Q2 2025.